All News
One Dose of HPV Vaccine May Protect against Cervical Cancer
Posted 1/13/2014A single dose of the cancer-fighting human papillomavirus (HPV) vaccine Cervarix™ appears to induce an immune response that remains stable in the blood four years after vaccination. This may be enough to protect women from two strains of HPV and, ultimately, from cervical cancer.
If these findings are confirmed in larger studies and for a longer follow-up time, not only…
Partnership to Explore New Drug Combination for Pancreatic Cancer
Posted 9/26/2013Scientists at NCI and Frederick National Laboratory for Cancer Research (FNL) are partnering with the Lustgarten Foundation to test whether a vitamin D derivative will make a difference when combined with a conventional anticancer drug in treating tumors of the pancreas.
The preclinical trials will be carried out in genetically engineered mice and represent the first in…
Novel Vaccine Approach Achieves “Functional Cure” of AIDS Virus in Monkeys
Posted 9/10/2013Scientists at the Oregon Health & Science University and the AIDS and Cancer Virus Program of the Frederick National Laboratory for Cancer Research have used a novel vaccine approach to achieve a “functional cure” and apparent eradication of infection with a monkey version of the AIDS virus.
In a paper published online in Nature, the group reported success with an…
Nanotechnology Laboratory Collaborates with Army to Develop Botulism Vaccine
Nanotechnology Characterization LaboratoryPosted 8/18/2013
The Nanotechnology Characterization Laboratory (NCL) is collaborating with the Army to develop a candidate vaccine against botulism.
Under a collaboration agreement between the National Cancer Institute and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), NCL scientists will produce nanoparticle formulations for four compounds that block the…
National Cancer Institute Advisory Board Gives Green Light to RAS Initiative
Posted 6/6/2013The Frederick National Laboratory for Cancer Research will spearhead a national R&D initiative focused on mutations in a family of genes called Ras, which play a role in 33 percent of all human cancers, including 90 percent of pancreatic cancers.
With unanimous concurrence of both the National Cancer Advisory Board (NCAB) and the National Cancer Institute (NCI)…
McCormick to Aid Frederick National Laboratory in Developing RAS Cancer Genetics Initiative
Posted 5/8/2013
Frank McCormick, Ph.D., director of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, and associate dean of the UCSF School of Medicine, has signed a consulting agreement with SAIC-Frederick Inc. to work with the Frederick National Laboratory for Cancer Research (FNLCR), on behalf of the National Cancer Institute (NCI), to…
NIH Director's Award Recognizes Rapid Response to Avert Potential Health Crisis
Posted 11/14/2012
In July 2012, members of a multidisciplinary research team of both SAIC-Frederick and NCI Center for Cancer Research scientists were recognized with the NIH Director’s Award for their outstanding work to rapidly evaluate a potential threat to the nation’s blood supply.
Known as the XMRV Working Group, the researchers came together in response to findings presented at…